Main characteristics of patients with HIV-2 that failed virologically under integrase inhibitors
| Patient no.a . | Gender (age, years) . | Country of origin . | HIV-2 subtype . | Antiretroviral regimen . | Undetectable VL (months) . | Resistance mutationsb . | ||
|---|---|---|---|---|---|---|---|---|
| integrase . | protease . | RT . | ||||||
| N_1 | M (13) | Equatorial Guinea | B | ABC + 3TC + RAL | no | N155H/E92Q | – | M184V |
| N_2 | M (40) | Guinea Bissau | A | TDF + FTC + DRV/r + RAL | no | N155H/E92Q/T97A | I54M/I82F/L90M | M184V |
| F_1 | M (63) | Guinea Bissau | unknown | TDF + FTC + DTG | no | – | – | – |
| F_2 | M (17) | Cabo Verde | A | ddI + MVC + DRV/r + RAL | no | N155H/A153G | I54M/I82F/L90M | K65R/Q151M |
| F_3 | M (51) | Mali | A | TDF + FTC + ATV/r + RAL | yes (14) | N155H/A153G | I84V/L90M | – |
| F_4 | M (58) | Spain | B | TDF + TPV/r + RAL | no | N155H/A153G | I54L/I82L | M184V |
| F_5 | M (49) | Senegal | A | TDF + FTC + DRV/r + RAL | yes (34) | – | – | M184V |
| F_6 | F (40) | Senegal | A | TDF + FTC + RAL | no | – | – | – |
| F_7 | M (40) | Guinea Bissau | A | TDF + DTG + DRV/r | no | Q148H/G140S | I50V | K65R |
| F_8 | F (38) | Portugal | A | TDF + FTC + RAL | yes (11) | Q148R/G140A | I82L/I84V | – |
| F_9 | M (48) | Senegal | A | DRV/r + MVC + RAL | no | Q148R/G140S | I50V | M184V |
| F_10 | M (53) | Senegal | B | DRV/c + DTG | yes (16) | R263K/E92G | I50V/I54L | K65R |
| F_11 | M (52) | Spain | B | TDF + DRV/r + RAL | no | Y143C | I54M/I84V | K65R |
| F_12 | M (47) | Africa | A | ZDV + 3TC + RAL | no | Y143C/E92Q | I54M/I82F | K65R/M184V |
| F_13 | M (37) | Guinea Bissau | A | TDF + FTC + RAL | no | Y143G/T97A/A153S | – | K65R/M184V |
| Patient no.a . | Gender (age, years) . | Country of origin . | HIV-2 subtype . | Antiretroviral regimen . | Undetectable VL (months) . | Resistance mutationsb . | ||
|---|---|---|---|---|---|---|---|---|
| integrase . | protease . | RT . | ||||||
| N_1 | M (13) | Equatorial Guinea | B | ABC + 3TC + RAL | no | N155H/E92Q | – | M184V |
| N_2 | M (40) | Guinea Bissau | A | TDF + FTC + DRV/r + RAL | no | N155H/E92Q/T97A | I54M/I82F/L90M | M184V |
| F_1 | M (63) | Guinea Bissau | unknown | TDF + FTC + DTG | no | – | – | – |
| F_2 | M (17) | Cabo Verde | A | ddI + MVC + DRV/r + RAL | no | N155H/A153G | I54M/I82F/L90M | K65R/Q151M |
| F_3 | M (51) | Mali | A | TDF + FTC + ATV/r + RAL | yes (14) | N155H/A153G | I84V/L90M | – |
| F_4 | M (58) | Spain | B | TDF + TPV/r + RAL | no | N155H/A153G | I54L/I82L | M184V |
| F_5 | M (49) | Senegal | A | TDF + FTC + DRV/r + RAL | yes (34) | – | – | M184V |
| F_6 | F (40) | Senegal | A | TDF + FTC + RAL | no | – | – | – |
| F_7 | M (40) | Guinea Bissau | A | TDF + DTG + DRV/r | no | Q148H/G140S | I50V | K65R |
| F_8 | F (38) | Portugal | A | TDF + FTC + RAL | yes (11) | Q148R/G140A | I82L/I84V | – |
| F_9 | M (48) | Senegal | A | DRV/r + MVC + RAL | no | Q148R/G140S | I50V | M184V |
| F_10 | M (53) | Senegal | B | DRV/c + DTG | yes (16) | R263K/E92G | I50V/I54L | K65R |
| F_11 | M (52) | Spain | B | TDF + DRV/r + RAL | no | Y143C | I54M/I84V | K65R |
| F_12 | M (47) | Africa | A | ZDV + 3TC + RAL | no | Y143C/E92Q | I54M/I82F | K65R/M184V |
| F_13 | M (37) | Guinea Bissau | A | TDF + FTC + RAL | no | Y143G/T97A/A153S | – | K65R/M184V |
M, male; F, female; VL, viral load; ABC, abacavir; 3TC, lamivudine; ZDV, zidovudine; ddI, didanosine; FTC, emtricitabine; TDF, tenofovir; RAL, raltegravir; DTG, dolutegravir; DRV, darunavir; ATV, atazanavir; LPV, lopinavir; TPV, tipranavir; r, ritonavir; c, cobicistat; MVC, maraviroc.
N, patient was treatment-naive; F, patient was treatment-experienced.
Mutations previously found at baseline are shown in bold.
Main characteristics of patients with HIV-2 that failed virologically under integrase inhibitors
| Patient no.a . | Gender (age, years) . | Country of origin . | HIV-2 subtype . | Antiretroviral regimen . | Undetectable VL (months) . | Resistance mutationsb . | ||
|---|---|---|---|---|---|---|---|---|
| integrase . | protease . | RT . | ||||||
| N_1 | M (13) | Equatorial Guinea | B | ABC + 3TC + RAL | no | N155H/E92Q | – | M184V |
| N_2 | M (40) | Guinea Bissau | A | TDF + FTC + DRV/r + RAL | no | N155H/E92Q/T97A | I54M/I82F/L90M | M184V |
| F_1 | M (63) | Guinea Bissau | unknown | TDF + FTC + DTG | no | – | – | – |
| F_2 | M (17) | Cabo Verde | A | ddI + MVC + DRV/r + RAL | no | N155H/A153G | I54M/I82F/L90M | K65R/Q151M |
| F_3 | M (51) | Mali | A | TDF + FTC + ATV/r + RAL | yes (14) | N155H/A153G | I84V/L90M | – |
| F_4 | M (58) | Spain | B | TDF + TPV/r + RAL | no | N155H/A153G | I54L/I82L | M184V |
| F_5 | M (49) | Senegal | A | TDF + FTC + DRV/r + RAL | yes (34) | – | – | M184V |
| F_6 | F (40) | Senegal | A | TDF + FTC + RAL | no | – | – | – |
| F_7 | M (40) | Guinea Bissau | A | TDF + DTG + DRV/r | no | Q148H/G140S | I50V | K65R |
| F_8 | F (38) | Portugal | A | TDF + FTC + RAL | yes (11) | Q148R/G140A | I82L/I84V | – |
| F_9 | M (48) | Senegal | A | DRV/r + MVC + RAL | no | Q148R/G140S | I50V | M184V |
| F_10 | M (53) | Senegal | B | DRV/c + DTG | yes (16) | R263K/E92G | I50V/I54L | K65R |
| F_11 | M (52) | Spain | B | TDF + DRV/r + RAL | no | Y143C | I54M/I84V | K65R |
| F_12 | M (47) | Africa | A | ZDV + 3TC + RAL | no | Y143C/E92Q | I54M/I82F | K65R/M184V |
| F_13 | M (37) | Guinea Bissau | A | TDF + FTC + RAL | no | Y143G/T97A/A153S | – | K65R/M184V |
| Patient no.a . | Gender (age, years) . | Country of origin . | HIV-2 subtype . | Antiretroviral regimen . | Undetectable VL (months) . | Resistance mutationsb . | ||
|---|---|---|---|---|---|---|---|---|
| integrase . | protease . | RT . | ||||||
| N_1 | M (13) | Equatorial Guinea | B | ABC + 3TC + RAL | no | N155H/E92Q | – | M184V |
| N_2 | M (40) | Guinea Bissau | A | TDF + FTC + DRV/r + RAL | no | N155H/E92Q/T97A | I54M/I82F/L90M | M184V |
| F_1 | M (63) | Guinea Bissau | unknown | TDF + FTC + DTG | no | – | – | – |
| F_2 | M (17) | Cabo Verde | A | ddI + MVC + DRV/r + RAL | no | N155H/A153G | I54M/I82F/L90M | K65R/Q151M |
| F_3 | M (51) | Mali | A | TDF + FTC + ATV/r + RAL | yes (14) | N155H/A153G | I84V/L90M | – |
| F_4 | M (58) | Spain | B | TDF + TPV/r + RAL | no | N155H/A153G | I54L/I82L | M184V |
| F_5 | M (49) | Senegal | A | TDF + FTC + DRV/r + RAL | yes (34) | – | – | M184V |
| F_6 | F (40) | Senegal | A | TDF + FTC + RAL | no | – | – | – |
| F_7 | M (40) | Guinea Bissau | A | TDF + DTG + DRV/r | no | Q148H/G140S | I50V | K65R |
| F_8 | F (38) | Portugal | A | TDF + FTC + RAL | yes (11) | Q148R/G140A | I82L/I84V | – |
| F_9 | M (48) | Senegal | A | DRV/r + MVC + RAL | no | Q148R/G140S | I50V | M184V |
| F_10 | M (53) | Senegal | B | DRV/c + DTG | yes (16) | R263K/E92G | I50V/I54L | K65R |
| F_11 | M (52) | Spain | B | TDF + DRV/r + RAL | no | Y143C | I54M/I84V | K65R |
| F_12 | M (47) | Africa | A | ZDV + 3TC + RAL | no | Y143C/E92Q | I54M/I82F | K65R/M184V |
| F_13 | M (37) | Guinea Bissau | A | TDF + FTC + RAL | no | Y143G/T97A/A153S | – | K65R/M184V |
M, male; F, female; VL, viral load; ABC, abacavir; 3TC, lamivudine; ZDV, zidovudine; ddI, didanosine; FTC, emtricitabine; TDF, tenofovir; RAL, raltegravir; DTG, dolutegravir; DRV, darunavir; ATV, atazanavir; LPV, lopinavir; TPV, tipranavir; r, ritonavir; c, cobicistat; MVC, maraviroc.
N, patient was treatment-naive; F, patient was treatment-experienced.
Mutations previously found at baseline are shown in bold.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
